Skip to content

Viridian Therapeutics

US · VRDN #2731 by market cap Listed 1970
29.96 -1.48 -4.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 31.45 +0.03%
After-hours 29.96 0.00%
31.4415.7329.962026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on VRDN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +12.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 15.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 23.6% Better than 23%
Operating margin -512.9% Better than 4%
Net margin -483.6% Better than 4%
Return on equity -63.9% Better than 8%
Return on invested capital -63.8% Better than 4%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 23.3% Better than 97%
6-month return 73.8% Better than 98%
12-month return (ex latest month) -26.3% Better than 11%
Distance below 52-week high 12.6% Better than 77%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 12.6x Better than 95%
Debt to assets 5.6% Better than 78%
Interest coverage -68.2x Better than 6%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 34.9% Better than 54%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.95%
1M +33.57%
3M +22.29%
6M +69.94%
YTD -3.73%
1Y +1.66%
3Y +85.05%
5Y +54.04%

Key statistics

Price & volume

Prev close
31.44
Open
31.12
Day range
29.87 - 31.75
Avg price
30.49
Volume
1.75M
Turnover
53.29M
Amplitude
5.98%
52-week range
13.18 - 34.29

Valuation

P/E
-9.02
P/E (TTM)
-7.78
P/B
7.05
EPS
-3.32
Net profit
-377.01M
Net assets
482.62M

Share structure

Market cap
3.40B
Float cap
2.97B
Shares out
113.56M
Float shares
99.06M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 79% of range
13.18 34.29

12.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-41.65M net over the window

Short interest

Shares short
17.04M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Viridian Therapeutics (VRDN)?

Viridian Therapeutics last traded at 29.96. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Viridian Therapeutics's market cap?

About 3.40B.

What is the P/E ratio of Viridian Therapeutics?

The trailing twelve-month P/E is -7.78. The Valuation tab shows it against the stock's own five-year range.

Does Viridian Therapeutics pay a dividend?

Viridian Therapeutics does not currently pay a regular dividend.

Is Viridian Therapeutics a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 40.43, which implies 34.9% upside from the current price. This is not investment advice.

What is Viridian Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Viridian Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Viridian Therapeutics discussion 0 comments

Add a comment